DR. SANG-MO KANG, MD
Radiology at Parnassus Ave, San Francisco, CA
License number
California G78412
Category
Radiology
Type
Surgery
License number
California G78412
Category
Radiology
Type
Surgical Oncology
Address
Address
400 Parnassus Ave, San Francisco, CA 94143
Phone
(415) 476-1551
(415) 353-8917 (Fax)
(415) 353-8917 (Fax)
Organization information
See more information about SANG-MO KANG at bizstanding.comSang-Mo Kang MD
505 Parnassus Ave, San Francisco, CA 94131
Industry:
Surgeons
Site:
Phone:
(415) 476-1236 (Phone)
Description:
There are 14 doctors at this site. Surgery is performed at this site.
Sang-Mo Mo Kang
Ucsf Liver Transplant - Sang-Mo Kang MD
505 Parnassus Ave #M896, San Francisco, CA 94143
Categories:
Gastroenterology Physicians & Surgeons, Nephrology Physicians & Surgeons, Physicians & Surgeons
Phone:
(415) 353-1888 (Phone)
Professional information
Sang-Mo Kang, San Francisco CA
Specialties:
Surgeon
Address:
505 Parnassus Ave, San Francisco, CA 94143
400 Parnassus Ave, San Francisco, CA 94143
400 Parnassus Ave, San Francisco, CA 94143
Education:
Harvard Medical School - Doctor of Medicine
Board certifications:
American Board of Surgery Certification in Surgery
Noncleavable Fas Ligand
US Patent:
6451759, Sep 17, 2002
Filed:
Jan 14, 1998
Appl. No.:
09/006755
Inventors:
Sang-Mo Kang - San Francisco CA
Andries Erik Braat - The Hague, NL
Steinunn Baekkeskov - San Francisco CA
Peter G. Stock - San Francisco CA
Andries Erik Braat - The Hague, NL
Steinunn Baekkeskov - San Francisco CA
Peter G. Stock - San Francisco CA
Assignee:
The Regents of the University of California - Oakland CA
International Classification:
A61K 3819
US Classification:
514 2, 530350, 530351, 4353201, 435325, 4353651, 4352523, 43525411, 536 235, 536 231, 424450
Abstract:
This invention generally provides polypeptides comprising a noncleavable form of a Fas ligand and having a capacity to activate a Fas receptor-mediated pathway involved in cell death, pharmaceutical compositions of such polypeptides, nucleic acids encoding such polypeptides, and cell lines capable of expressing these nucleic acids. Also provided are therapeutic and prophylactic methods of using such polypeptides, compositions, and cells lines for treating patients suffering from disorders resulting from dysregulation or inappropriate stimulation of the Fas receptor-mediated pathway.
Modulation Of Nkg2D For Treating Or Preventing Solid Organ Allograft Rejection
US Patent:
7998481, Aug 16, 2011
Filed:
May 5, 2006
Appl. No.:
11/429354
Inventors:
Sang-Mo Kang - San Francisco CA, US
Lewis L. Lanier - San Francisco CA, US
Lewis L. Lanier - San Francisco CA, US
Assignee:
The Regents of the University of California - Oakland CA
International Classification:
A61K 39/40, A61K 35/28, A01N 25/00
US Classification:
4241391, 424577, 514885
Abstract:
The present invention relates to methods and compositions for treating and/or preventing autoimmune and/or inflammatory disease. In particular, the present invention provides therapeutics for impairing the expansion and function of autoreactive T cells, NK cells and/or NKT cells, by modulating NKG2D.
Modulation Of Nkg2D
US Patent:
2010018, Jul 22, 2010
Filed:
May 4, 2007
Appl. No.:
12/299608
Inventors:
Jody L. Baron - Mill Valley CA, US
Sang-Mo Kang - San Francisco CA, US
Lewis L. Lanier - San Francisco CA, US
Sang-Mo Kang - San Francisco CA, US
Lewis L. Lanier - San Francisco CA, US
Assignee:
Regents of the University of California - Oakland CA
International Classification:
A61K 39/42, A61P 31/12, A61K 31/7088
US Classification:
4241331, 4241611, 4241491, 4241421, 514 44 R
Abstract:
The present invention relates to methods and compositions for treating and/or preventing inflammation associated with viral infection and solid organ transplant rejection. In particular, the present invention provides therapeutics for impairing the expansion and function of autoreactive T cells, NK cells and/or NKT cells, by modulating NKG2D.